US2012177705A1PendingUtilityA1

Composition 064

33
Assignee: BLYTH JOHN DAVIDPriority: Oct 12, 2007Filed: Mar 21, 2012Published: Jul 12, 2012
Est. expiryOct 12, 2027(~1.2 yrs left)· nominal 20-yr term from priority
Inventors:John David BlythAndrew John DayKieran James Lennon
A61P 43/00A61P 35/00A61K 9/2054A61K 9/1623A61K 31/495A61K 9/2018A61K 31/497
33
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pharmaceutical composition which comprises N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide with mannitol and/or microcrystalline cellulose is described.

Claims

exact text as granted — not AI-modified
1 - 19 . (canceled) 
     
     
         20 . A pharmaceutical composition comprising zibotentan, a pigmented film-coat and a filler. 
     
     
         21 . A pharmaceutical composition as claimed in  claim 20  wherein, the filler is microcrystalline cellulose and/or mannitol. 
     
     
         22 . A pharmaceutical composition as claimed in  claim 20  in the form of a tablet or a capsule. 
     
     
         23 . A pharmaceutical composition comprising a filler, zibotentan and a coating comprising one or more coloring agents wherein the pharmaceutical composition is in the form of a tablet. 
     
     
         24 . A pharmaceutical composition as claimed in  claim 23  with a coating comprising three coloring agents. 
     
     
         25 . A pharmaceutical composition as claimed in  claim 23  wherein, the coating contains from 0.5 to 10% by weight of coloring agent. 
     
     
         26 . A pharmaceutical composition as claimed in  claim 25  wherein, it contains 1 to 2% by weight of coloring agent. 
     
     
         27 . A pharmaceutical composition as claimed in either  claim 23  wherein, the coating comprises an iron oxide pigment. 
     
     
         28 . A pharmaceutical composition as claimed in  claim 27  wherein, the coating comprising iron oxide yellow, iron oxide red and iron oxide black. 
     
     
         29 . A pharmaceutical composition comprising a filler, zibotentan and a coating comprising one or more opacifiers wherein the pharmaceutical composition is in the form of a tablet. 
     
     
         30 . A pharmaceutical composition as claimed in  claim 29  wherein, the coating comprising titanium dioxide. 
     
     
         31 . A pharmaceutical composition as claimed in  claim 29  wherein, the coating contains from 20 to 40% by weight of opacifier. 
     
     
         32 . A pharmaceutical composition as claimed in  claim 31  wherein, the coating contains 27.5 to 31.5% by weight of opacifier. 
     
     
         33 . A pharmaceutical composition as claimed in  claim 29  wherein, the coating comprises one or more film formers. 
     
     
         34 . A pharmaceutical composition as claimed in  claim 29  wherein, the coating is between 1 to 10% by weight of the tablet core weight. 
     
     
         35 . A pharmaceutical composition as claimed in  claim 34  wherein, the coating is between 3 to 6% by weight of the tablet core weight. 
     
     
         36 . A composition as claimed in  claim 35  wherein, the coating is 3 to 4% by weight of the tablet core weight. 
     
     
         37 . A pharmaceutical composition as claimed in  claim 20  wherein, the coating comprises one or more film formers. 
     
     
         38 . A pharmaceutical composition as claimed in  claim 20  wherein, the coating is between 1 to 10% by weight of the tablet core weight. 
     
     
         39 . A pharmaceutical composition as claimed in  claim 23  wherein, the coating comprises one or more film formers.

Join the waitlist — get patent alerts

Track US2012177705A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.